Aim: This study aims to investigate any modification of serological FSCN1 in prostate cancer patients compared with patients without neoplasia.
Material & methods: Clinical data and blood specimens from patients with and without prostate cancer were obtained. A quantitative sandwich ELISA method was used to determine serological values of FSCN1.
Results: Although serum values of FSCN1 were dissimilar in the two cohorts of patients (6.90 vs 7.33 ng/ml), the difference was not statistically significant (p = 0.20). Serum values of FSCN1 stratified for Gleason score groups were not significantly distinguishable (p = 0.65). A negative correlation (rho = -0.331; p = 0.009) was reported between FSCN1 and age.
Conclusion: Further studies are required to evaluate a possible diagnostic role of FSCN1 in prostate cancer.